there is now considerable recent experience with the use of these antibiotics for selected serious pediatric infections Furthermore, the risk of morbidity and mortality from these biologic agent–induced diseases far outweighs the minor risks (tendinopathy with fluoroquinolones, dental staining with tetracyclines) associated with short-term pediatric use of these medications In fact, ciprofloxacin, levofloxacin, and doxycycline have lower risk of these adverse effects and are approved by the U.S Food and Drug Administration (FDA) for use in children for the treatment and prophylaxis of anthrax and plague following inhalational exposure (i.e., in the context of terrorism)